Ocugen Inc. (OCGN)
NASDAQ: OCGN
· Real-Time Price · USD
1.03
0.00 (0.00%)
At close: Aug 15, 2025, 12:52 PM
0.00% (1D)
| Bid | 1.03 |
| Market Cap | 321.96M |
| Revenue (ttm) | 4.75M |
| Net Income (ttm) | -56.94M |
| EPS (ttm) | -0.19 |
| PE Ratio (ttm) | -5.43 |
| Forward PE | -3.99 |
| Analyst | Buy |
| Ask | 1.04 |
| Volume | 623,666 |
| Avg. Volume (20D) | 5,551,179 |
| Open | 1.02 |
| Previous Close | 1.03 |
| Day's Range | 1.02 - 1.04 |
| 52-Week Range | 0.52 - 1.40 |
| Beta | 3.85 |
About OCGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OCGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for OCGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Ocugen Inc. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-7.44%
Ocugen shares are trading lower after after the co...
Unlock content with
Pro Subscription
2 months ago
+2.65%
Ocugen shares are trading higher after the FDA cleared its IND amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST for Stargardt disease.
